← Back to Clinical Trials
Recruiting NCT06404320

NCT06404320 Physical Activity Program for TRD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06404320
Status Recruiting
Phase
Sponsor Unity Health Toronto
Condition Treatment-resistant Depression
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-09-19
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
PA program - MoveU.HappyU

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-09-19 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).

Eligibility Criteria

Inclusion Criteria: 1. Sedentary adults (engage in less than 60 minutes of moderate-to-vigorous PA per week) between the ages of 18 and 65 years, inclusive, capable of giving informed consent. 2. Participants meeting diagnostic criteria for major depressive disorder without psychotic symptoms according to the Diagnostic and Statistical Manual of Mental Disorders - 5th Ed. and currently experiencing a major depressive episode (MDE) as confirmed by the Mini International Neuropsychiatric Interview (MINI). 3. A Montgomery-Åsberg Depression Rating Scale total score of ≥ 7 at screening (mild-to-severe MDE). 4. Failure of at least two trials of antidepressant therapy of adequate dose and duration during the current episode as established by the Antidepressant Treatment History Form and self-report. 5. Receiving treatments congruent with Canadian Network for Mood and Anxiety Treatments guidelines with no changes to treatments one month before screening (28 days). Exclusion Criteria: 1. Current symptoms of mania, hypomania, mixed episodes, or psychosis. 2. Have received a diagnosis of alcohol or a substance use disorder within the past 3 months or as confirmed by the MINI. Other secondary psychiatric comorbidities (e.g., anxiety disorders, trauma-related disorders, etc.) will not be excluded. 3. Pregnant females. 4. Acute risk for a cardiovascular event (i.e., cardiovascular event in the past within the past 12 months). 5. Have any medical contraindications to exercise according to the Physical Activity Readiness Questionnaire. 6. Self-reported balance, gait, or locomotion difficulties that would preclude participation in a PA program. 7. Have any other condition that, in the opinion of the investigator(s), would adversely affect the subject's ability to complete the study or its measures. 8. Have exercise-induced asthma. 9. Taking medication that interferes with heart rate response to exercise, such as beta blockers. 10. Do not own a smartphone. 11. Do not have reliable access to the Internet. 12. Have previously received intravenous ketamine treatment in the last 2 months. Non-English-speaking individuals are excluded because the ability to communicate study information, answer questions accurately and completely about the study, and obtain consent are necessary.

Contact & Investigator

Central Contact

Venkat Bhat

✉ venkat.bhat@utoronto.ca

📞 416-360-4000

Frequently Asked Questions

Who can join the NCT06404320 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Treatment-resistant Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06404320 currently recruiting?

Yes, NCT06404320 is actively recruiting participants. Contact the research team at venkat.bhat@utoronto.ca for enrollment information.

Where is the NCT06404320 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT06404320 clinical trial?

NCT06404320 is sponsored by Unity Health Toronto. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology